DONE Genetics and Bioinformatics Inc.

We have been providing high quality services in genomics and bioinformatics fields since 2009. Our experience in genomic studies ensures we can handle your needs efficiently, fast, with the high quality and at a price to keep you on budget. In addition to our genomic services, we are also providing variety of training programs about popular subjects in genomics and bioinformatics fields.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

GENOMICS TESTING COMPANIES AND LABORATORIES COMBINE EFFORTS TO ESTABLISH THE CARDIOGENOMIC TESTING ALLIANCE

CardioGenomic | March 23, 2022

news image

Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade test...

Read More

MEDICAL

GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550, FOR TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES

GT Biopharma | December 23, 2020

news image

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, i...

Read More

SAMSUNG BIOLOGICS, VIR BIOTECHNOLOGY TEAM UP TO FIGHT COVID-19

BioSpectrum Asia | April 13, 2020

news image

South Korea based Samsung Biologics and US based Vir Biotechnology, Inc. have announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services Vir's SARS-CoV-2 monoclonal antibody (mAb) program. Vir's lead SRS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly i...

Read More

CELL AND GENE THERAPY

ASTELLAS AND DYNO THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION TO DEVELOP NEXT-GENERATION AAV GENE THERAPY VECTORS FOR SKELETAL AND CARDIAC MUSCLE

Astellas Pharma Inc. and Dyno Therapeutics, Inc. | December 02, 2021

news image

Astellas Pharma Inc. and Dyno Therapeutics, Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform. Dyno's CapsidMap platform represents a transformative approach applying in vivo experimental data and machine learning to create novel AAV capsids – the cell-targeting protein shells of viral vectors...

Read More
news image

CELL AND GENE THERAPY

GENOMICS TESTING COMPANIES AND LABORATORIES COMBINE EFFORTS TO ESTABLISH THE CARDIOGENOMIC TESTING ALLIANCE

CardioGenomic | March 23, 2022

Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA will inform healthcare providers and other stakeholders to the value of such testing to assure adherence to existing guidelines from professional medical societies, inform medical management and cascade test...

Read More
news image

MEDICAL

GT BIOPHARMA ANNOUNCES FDA DATA - GTB-3550, FOR TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES

GT Biopharma | December 23, 2020

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS). Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, i...

Read More
news image

SAMSUNG BIOLOGICS, VIR BIOTECHNOLOGY TEAM UP TO FIGHT COVID-19

BioSpectrum Asia | April 13, 2020

South Korea based Samsung Biologics and US based Vir Biotechnology, Inc. have announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services Vir's SARS-CoV-2 monoclonal antibody (mAb) program. Vir's lead SRS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly i...

Read More
news image

CELL AND GENE THERAPY

ASTELLAS AND DYNO THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION TO DEVELOP NEXT-GENERATION AAV GENE THERAPY VECTORS FOR SKELETAL AND CARDIAC MUSCLE

Astellas Pharma Inc. and Dyno Therapeutics, Inc. | December 02, 2021

Astellas Pharma Inc. and Dyno Therapeutics, Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform. Dyno's CapsidMap platform represents a transformative approach applying in vivo experimental data and machine learning to create novel AAV capsids – the cell-targeting protein shells of viral vectors...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us